89 related articles for article (PubMed ID: 3330400)
1. [Prevention and treatment of graft-versus-host disease].
Wiktor-Jedrzejczak W
Acta Haematol Pol; 1987; 18(3-4):220-4. PubMed ID: 3330400
[No Abstract] [Full Text] [Related]
2. [Immunosuppressive drugs in the prevention and treatment of GVHD after allogenic bone marrow transplantation].
Basić-Jukić N; Labar B
Acta Med Croatica; 2003; 57(2):131-9. PubMed ID: 12879693
[TBL] [Abstract][Full Text] [Related]
3. [Bone marrow transplantation in the treatment of acute childhood leukosis].
Muñoz Villa A; Madero López L
An Esp Pediatr; 1983 Sep; 19 Suppl 19():52-5. PubMed ID: 6362507
[No Abstract] [Full Text] [Related]
4. [Graft-versus-host disease].
Svedentsov EP; Sharygin SL; Epifanov NS; Matveev GA
Klin Med (Mosk); 1993; 71(5):19-23. PubMed ID: 8301977
[No Abstract] [Full Text] [Related]
5. Is there an effective therapy for chronic graft-versus-host disease?
Schiller G; Gale RP
Bone Marrow Transplant; 1993 Mar; 11(3):189-92. PubMed ID: 8467281
[No Abstract] [Full Text] [Related]
6. Immunosuppressive power and limitations of FK 506 for prevention and treatment of graft-vs-host disease after small bowel transplantation.
Platz KP; Mueller AR; Langrehr JM; Neuhaus P; Schraut WH
Transplant Proc; 1996 Oct; 28(5):2523-4. PubMed ID: 8907933
[No Abstract] [Full Text] [Related]
7. The potential utility of statins as novel weapons against graft-versus-host disease.
Namazi MR; Handjani F; Sodaifi M
Med Hypotheses; 2005; 65(6):1203-4. PubMed ID: 16139438
[No Abstract] [Full Text] [Related]
8. Pemphigoid-like ocular lesions in patients with graft-versus-host disease following allogeneic bone marrow transplantation.
Karwacka E; Ołdakowska-Jedynak U; Brydak-Godowska J; Paczek L; Kecik D
Transplant Proc; 2006; 38(1):292-4. PubMed ID: 16504728
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
Schwinghammer TL; Bloom EJ
Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255
[TBL] [Abstract][Full Text] [Related]
10. Inolimomab (OPi).
Winkler M
Curr Opin Investig Drugs; 2002 Oct; 3(10):1464-7. PubMed ID: 12431019
[TBL] [Abstract][Full Text] [Related]
11. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation.
Atkinson K; Downs K
Bone Marrow Transplant; 1995 Dec; 16(6):755-8. PubMed ID: 8750265
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive agents.
Dannie E
Nurs Times; 1993 Jan 27-Feb 2; 89(4):34-7. PubMed ID: 8437902
[No Abstract] [Full Text] [Related]
13. Syngeneic graft-versus-host disease: a report of two cases and literature review.
Latif T; Pohlman B; Kalaycio M; Sobecks R; Hsi ED; Andresen S; Bolwell BJ
Bone Marrow Transplant; 2003 Sep; 32(5):535-9. PubMed ID: 12942102
[TBL] [Abstract][Full Text] [Related]
14. An old drug for a new disease: pentostatin (Nipent) in acute graft-versus-host disease.
Margolis J; Vogelsang G
Semin Oncol; 2000 Apr; 27(2 Suppl 5):72-7. PubMed ID: 10877057
[TBL] [Abstract][Full Text] [Related]
15. FK506 (tacrolimus) in the treatment of steroid-resistant acute graft-versus-host disease in children undergoing bone marrow transplantation.
Koehler MT; Howrie D; Mirro J; Neudorf S; Blatt J; Corey S; Wollman M; Kelly-Ekeroth V; Reyes J
Bone Marrow Transplant; 1995 Jun; 15(6):895-9. PubMed ID: 7581088
[TBL] [Abstract][Full Text] [Related]
16. Atypical acute graft-versus-host disease.
Shin J; Hong W; Song H; Choi G; Kim YC
Am J Dermatopathol; 2007 Dec; 29(6):576-7. PubMed ID: 18032957
[TBL] [Abstract][Full Text] [Related]
17. The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children.
Rovelli A; Arrigo C; Nesi F; Balduzzi A; Nicolini B; Locasciulli A; Vassallo E; Miniero R; Uderzo C
Bone Marrow Transplant; 1998 Mar; 21(6):577-81. PubMed ID: 9543061
[TBL] [Abstract][Full Text] [Related]
18. Sclerodermatous chronic graft-versus-host disease--a report of four pediatric cases.
Tolland JP; Devereux C; Jones FC; Bingham EA
Pediatr Dermatol; 2008; 25(2):240-4. PubMed ID: 18429789
[TBL] [Abstract][Full Text] [Related]
19. Prevention of graft-versus-host disease by immunosuppressive agents after transplantation of DLA-nonidentical canine marrow.
Storb R; Kolb HJ; Deeg HJ; Weiden PL; Appelbaum F; Graham TC; Thomas ED
Bone Marrow Transplant; 1986 Dec; 1(2):167-77. PubMed ID: 3332131
[TBL] [Abstract][Full Text] [Related]
20. Re: Twenty-year follow-up in patients with aplastic anemia given marrow grafts from HLA-identical siblings and randomized to receive methotrexate/cyclosporine or methotrexate alone for prevention of graft-versus-host disease.
Sorror ML; Leisenring W; Deeg HJ; Martin PJ; Storb R
Biol Blood Marrow Transplant; 2005 Jul; 11(7):567-8. PubMed ID: 15983557
[No Abstract] [Full Text] [Related]
[Next] [New Search]
